Payers

Latest News

In a 100-patient clinical practice scenario, cost savings with zanubrutinib vs ibrutinib would amount to $4.7 million. | Image credit: sovova - stock.adobe.com
Zanubrutinib May Lead to Cost Savings vs Ibrutinib in R/R CLL

April 15th 2025

Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory chronic lymphocytic leukemia (CLL), new research suggests.

None of the eteplirsen-treated patients reached an LVEF below 50%, compared with 22.1% of patients in the control group. | Image credit: inthasone - stock.adobe.com
Eteplirsen Treatment Linked to Slower Cardiac Decline in DMD

April 11th 2025

Seniors receiving health care | Image credit: Adobe.com
Sutter Health, SCAN Announce Partnership to Launch New MA Products, Joint Venture Health Plan

April 11th 2025

Patient self reporting or intentional physical examinations by clinicians remain the main avenues by which suspected skin cancers are identified. | Image credit: anna.stasiia - stock.adobe.com
Novel Methods Could Reshape Skin Cancer Diagnostics

April 10th 2025

Based on the model, over 3 million MACE were projected over the following 10 years, approximately 496,000 of which could be prevented with the use of semaglutide. | Image credit: peter hansen - stock.adobe.com
Semaglutide Use Could Prevent Up to 2 Million MACE in 10 Years, Model Suggests

April 9th 2025

More News

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo